Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$0.12 and last traded at C$0.12, with a volume of 60720 shares changing hands. The stock had previously closed at C$0.13.
Hemostemix Price Performance
The firm has a market capitalization of C$10.45 million, a PE ratio of -6.00 and a beta of 0.20. The company’s fifty day simple moving average is C$0.08 and its 200 day simple moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What Does Downgrade Mean in Investing?
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- How Investors Can Find the Best Cheap Dividend Stocks
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- How to Calculate Inflation Rate
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
